396 related articles for article (PubMed ID: 19395877)
21. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
22. [Prostate cancer: the revolution of the fusion genes].
Fernández-Serra A; Rubio-Briones J; García-Casado Z; Solsona E; López-Guerrero JA
Actas Urol Esp; 2011; 35(7):420-8. PubMed ID: 21601955
[TBL] [Abstract][Full Text] [Related]
23. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development.
Attard G; Ang JE; Olmos D; de Bono JS
J Clin Pathol; 2008 Aug; 61(8):891-6. PubMed ID: 18495790
[TBL] [Abstract][Full Text] [Related]
24. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M; Schalken JA
J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
[TBL] [Abstract][Full Text] [Related]
25. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
Rubin MA; Chinnaiyan AM
Lab Invest; 2006 Nov; 86(11):1099-102. PubMed ID: 16983328
[TBL] [Abstract][Full Text] [Related]
26. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
[TBL] [Abstract][Full Text] [Related]
27. [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
Beuzeboc P; Soulié M; Richaud P; Salomon L; Staerman F; Peyromaure M; Mongiat-Artus P; Cornud F; Paparel P; Davin JL; Molinié V
Prog Urol; 2009 Dec; 19(11):819-24. PubMed ID: 19945666
[TBL] [Abstract][Full Text] [Related]
28. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
Guo XQ; Gui YT; Cai ZM
Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
[TBL] [Abstract][Full Text] [Related]
29. TMPRSS2-ERG gene fusion in prostate cancer.
Burdova A; Bouchal J; Tavandzis S; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):502-10. PubMed ID: 25485532
[TBL] [Abstract][Full Text] [Related]
30. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
Rouzier C; Haudebourg J; Carpentier X; Valério L; Amiel J; Michiels JF; Pedeutour F
Cancer Genet Cytogenet; 2008 May; 183(1):21-7. PubMed ID: 18474293
[TBL] [Abstract][Full Text] [Related]
31. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
32. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
33. Recurrent gene fusions in prostate cancer: their clinical implications and uses.
Hessels D; Schalken JA
Curr Urol Rep; 2013 Jun; 14(3):214-22. PubMed ID: 23625457
[TBL] [Abstract][Full Text] [Related]
34. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.
Hermans KG; Bressers AA; van der Korput HA; Dits NF; Jenster G; Trapman J
Cancer Res; 2008 May; 68(9):3094-8. PubMed ID: 18451133
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB
Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal aberrations in solid tumors.
Chinnaiyan AM; Palanisamy N
Prog Mol Biol Transl Sci; 2010; 95():55-94. PubMed ID: 21075329
[TBL] [Abstract][Full Text] [Related]
37. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
39. [Molecular biology and prostate cancer: evolution or revolution?].
Molinié V; Beuzeboc P; Mahjoub WK;
Ann Pathol; 2008 Oct; 28(5):354-62. PubMed ID: 19068390
[TBL] [Abstract][Full Text] [Related]
40. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression.
St John J; Powell K; Conley-Lacomb MK; Chinni SR
J Cancer Sci Ther; 2012 Apr; 4(4):94-101. PubMed ID: 23264855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
